You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

National Viral Hepatitis Roundtable Applauds National AIDS Strategy's Recognition of HIV/HCV Coinfection

SUMMARY: The National Viral Hepatitis Roundtable (NVHR) praised the inclusion of hepatitis B and C coinfection in the White House Office of National AIDS Policy's National HIV/AIDS Strategy released last week, given that an about 30% of HIV positive people also have HCV and approximately 10% also have HBV. The advocates also expressed hope that the administration will take a similar comprehensive approach to hepatitis B and C monoinfection, the latter of which affects about 4 times as many people as HIV.

Below is the text of a press release issued by the National Viral Hepatitis Roundtable.

NVHR: Administration's National HIV/AIDS Strategy
Recognizes Need for Better Care Coordination for
Individuals Co-Infected with Viral Hepatitis

Washington, DC -- July 14, 2010 -- With millions of Americans living with HIV/AIDS, chronic viral hepatitis, or a combination of both, the National Viral Hepatitis Roundtable (NVHR) welcomes the Administration's recognition of the need for better care coordination and integration of services for these individuals and supports recommendations contained within the new National HIV/AIDS Strategy released yesterday in Washington. As the Administration's interagency working group on viral hepatitis works to meet an October 1, 2010 deadline for its own action plan, NVHR is hopeful that we will see a similar national commitment from the Administration. An estimated 5.3 million Americans are infected with chronic viral hepatitis, which is 4 times the estimated HIV/AIDS population. Chronic viral hepatitis is a leading cause of death in HIV patients in America.

"NVHR welcomes the Administration's recognition of the need for better care coordination for individuals afflicted with HIV/AIDS," said Ms. Lorren Sandt, NVHR Chair and Executive Director of Caring Ambassadors Program, based in Portland, OR. "With approximately 30 percent of all individuals living with HIV/AIDS co-infected with hepatitis C and 10 percent co-infected with hepatitis B, an integrated, comprehensive strategy is critical if we are going to win the war against these insidious diseases. The outdated 'silo' approach undermines quality and leads to higher costs throughout the system."

The Administration's national HIV/AIDS strategy provides a model for how to galvanize the entire public health infrastructure into action. With policymakers, clinicians, and others stakeholders seeking to transform our system into one based on preventive care, early intervention to screen, detect, and treat viral hepatitis is essential. With most Americans unaware they are infected, chronic viral hepatitis progresses far too often to liver cancer, cirrhosis, or liver failure. Delayed screening and treatment leads to billions of dollars in avoidable health care costs. Milliman estimates that public and private payers' cost of treating chronic viral hepatitis C alone will more than triple by 2024 to $85 billion unless Washington acts. While proposed legislation would help address this crisis, NVHR believes more needs to be done.

"Just like yesterday's HIV/AIDS announcement, the viral hepatitis plague demands leadership from the highest levels of the federal government," added Ms. Sandt. "Otherwise, millions of Americans will be at risk of developing life-threatening complications."

About NVHR

NVHR is a coalition of more than 150 public, private, and voluntary organizations dedicated to reducing the incidence of infection, morbidity, and mortality from chronic viral hepatitis that afflicts more than 5 million Americans.

For more information, see www.nvhr.org.

7/20/10

Source
National Viral Hepatitis Roundtable. NVHR: Administration's National HIV/AIDS Strategy Recognizes Need for Better Care Coordination for Individuals Co-Infected with Viral Hepatitis. Press release. July 14, 2010.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 Google Custom Search

HIV-HCV Confection
Main Section


International Guidelines for Management of HIV-HCV Coinfection


FDA-approved Combination Therapies for Chronic HCV Infection
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin

Treatment Guidelines
FDA-approved Combination Therapies for HIV and AIDS Infection

Protease Inhibitors PIs
non Nucleoside Reverse
  
Transcriptase Inhibitors nNRTIs
Nucleoside / Nucleotide Reverse
  
Transcriptase Inhibitors NRTIs

Fixed-dose Combinations

Entry / Fusion Inhibitors EIs
Integrase Inhibitors